Melphalan is an efficient chemotherapeutic agent that is currently used to treat retinoblastoma (Rb); however, the inherent risk of immunogenicity and the hazardous integration of this drug in healthy cells is inevitable. MicroRNAs are short non-coding single-stranded RNAs that affect a vast range of biological processes. Previously, we focused on the regulatory role of miR-181a during cancer development and progression. In this manuscript, 171 nm switchable lipid nanoparticles (LNP) co-delivered melphalan and miR-181a with encapsulation efficiencies of 93%. Encapsulation of melphalan in LNP significantly improved its therapeutic efficiency. Gene analysis shows that miR-181a decreases the expression of anti-proliferative gene MAPK1 and antiapoptotic gene Bcl-2, but significantly increased the expression of pro-apoptotic gene BAX. Our results suggest that the two agents have a complementary effect in reducing the viability of cultured Rb cells (primary and cell line) and decreasing Rb cell counts in an in-vivo xenograft Rb model in rats. Our results suggest that the proposed co-delivery technique significantly increases the therapeutic impact, allows for lower administration of melphalan, and consequently, could minimize the cytotoxic side-effects of this drug.
Introduction
Retinoblastoma (Rb) is the most common pediatric cancer of the eye and accounts for 3% of all childhood malignancies [1] . It affects very young children with > 90% of cases diagnosed before 5 years of age. Treatment of Rb with current remedies includes intra-arterial or intravitreal injections of chemotherapeutic agents. It has been reported that intra-arterial injection of melphalan can lead to pulmonary toxicity [2] , arrhythmias [3] , and other cytotoxic side effects [4, 5] . On the other hand, while systemic toxicity with intra-vitreal injection of melphalan has not been detected, reduced electroretinogram response of the retina post injection is indicative of retinal toxicity [6] . For early stages of Rb the latter administration route has become a common practice among pediatricians, however vitreous seeding remains a major cause of treatment failure [6, 7] in which case enucleation becomes the unfortunate alternative [8] . Previously, we examined the therapeutic effect of microparticles secreted from apoptotic human T-lymphocytes (LMPs) as an alternative to chemotherapeutics [9] [10] [11] . LMPs exhibited anti-tumor effects on mouse Lewis lung carcinoma cells, HeLa cells, human breast cancer, and Rb cells [12, 13] . The LMPs contain a large number of proteins, DNA fragments, membrane receptors, enzymes, small RNAs, etc., but our recent analysis by RNA sequencing provides evidence that the most abundant element confined within the LMPs is a microRNA called miR-181a. MicroRNAs are short non-coding RNAs that affect a vast range of biological processes (cell proliferation, differentiation, survival, and motility) and are critical regulators in human disease [14] . In particular, miR-181a, a 21 nucleotide RNA sequence, is downregulated in various cancer cells including human malignant glioma cells, oral squamous carcinoma cells, and non-small lung cancer cells [15] [16] [17] . There is a mounting interest in therapeutic effect of microRNAs as complementary therapy to chemotherapy. Studies show that co-delivery of microRNAs and chemotherapeutic agents can https://doi.org/10.1016/j.jconrel.2019.02.014 Received 24 August 2018; Received in revised form 31 December 2018; Accepted 12 February 2019 enhance the therapeutic outcome by regulating chemosensitivity in malignant cells [18] [19] [20] . Therefore, for the same dosage, the treatment efficacy is enhanced, which in turn improves the overall outcome of the treatment. However, the efficacy of nucleic acid therapeutics such as miR-181a relies mainly on their successful delivery to target cells. The advent of microfabrication in pharmaceutics has inspired miniaturized drug delivery systems for biological research. In fact, nanoparticlebased systems designed for the treatment of ocular disorders including Rb have improved rates of drug delivery to the anterior and posterior segments of the eye and have increased the intra-vitreal half-life of chemotherapeutic agents [5, 21, 22] . Switchable lipids nanoparticles (LNP) are the most advanced system of gene delivery in clinics [23, 24] . Recently, these particles have been reported to enable massive delivery to the cytoplasm due to their endosomal escape ability [25] . Incorporation of siRNAs into LNP enabled significant transfection efficiency in-vitro and in-vivo [26] . In this investigation, melphalan-loaded in LNP are engineered to enhance targeting of Rb cells and decrease cytotoxic side effects. In addition, the genetic downstream effects of miR-181a was investigated. Finally, the complementary effect of melphalan and miR-181a-loaded particles was used to increase treatment efficiency in a Rb xenograft rat model, which represents the most severe case of Rb seeds in the vitreous [6] .
Materials and methods
miR-181a mimic was purchased from Life Technologies (hsa-miR181a-5p, mirVana® miRNA mimic, matured sequence: AACAUUCAAC GCUGUCGGUGAGU) and melphalan was purchased from Alkeran (Aspen Toronto, Canada). The cationic switchable lipid (CSL3) was synthesized as previously reported [25, 26] . 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine)-N-[(polyethylene glycol)-2000 (DSPE-PEG 2000 ) were purchased from Avanti Polar Lipids (Alabaster, AL, USA). Cholesterol and other chemicals were purchased from Sigma Aldrich (Canada).
LNP formulation
The stock solutions of CSL3, DSPC, cholesterol and DSPE-PEG 2000 in ethanol were mixed in a 5 mL round-bottom flask to get the final composition (CSL3/DSPC/cholesterol/DSPE-PEG 2000 -50:10:37.5:2.5 mol%). To prepare melphalan-loaded LNP (LNP/melphalan), melphalan at 1 mg/mL in ethanol was added to the lipid mixture to reach 10 mol% of total lipids. Ethanol was evaporated under reduced pressure. The lipid film was hydrated with 5% dextrose in water for 30 min at 40°C. Dextrose 5% was selected to provide isoosmolar conditions compatible with biological media. In addition, our previous observations suggest that colloidal stability upon complexation has been enhanced in dextrose 5% than in other buffers. The lipid suspension was extruded at 50°C through polycarbonate membranes (400, 200 and 100 nm) using a LiposoFast manual extruder (Avestin Inc., Canada). The miR-181a mimic was complexed to the LNP (LNP/miR-181a) in a nitrogen/phosphate (N/P) ratio of 4. LNP in dextrose 5% and miR-181a in dextrose 5% were then mixed at equal volume and incubated for 15 mins at 50°C, 400 rpm in Labnet Vortemp™56.
Melphalan quantification
LNP (with or without 10 mol% melphalan) were diluted 10 times in methanol for direct quantification of CSL3. The encapsulation efficiency of melphalan was determined by an indirect method; LNP containing melphalan 10 mol% were prepared as above and centrifuged for 1 h at 14,000 rpm. The supernatant was diluted 5 times in methanol, quantified via HPLC and compared to the initial melphalan quantified in the stock solution by the same method. CSL3 was quantified against a calibration curve (CSL3 25-250 μg/mL from ethanol stock solution) via HPLC. The HPLC-UV/MS system (Agilent Technologies 1260 Infinity) was equipped with a PDA detector, a quadrupole MS (Agilent technologies 6120), and a column (Agilent Poroshell 120 EC -C8 (2.7 m) 3 × 30 mm). The same method was used to quantify melphalan and CSL3. Mobile phase A was composed of water/acetonitrile 95/ 5 + 0.1% acetic acid and mobile phase B was composed of acetonitrile +0.1% acetic acid. The mobile phase gradient was: 0 min -90% A; 1 min -100% B; followed by a column re-equilibration time of 3 min with the following properties: Flow 1.5 mL/min; UV detection: 205 nm (melphalan) and 254 nm (CSL3); Injection volume: 5 μL.
The melphalan encapsulation efficiency was calculated as follows:
(1)
miR-181a encapsulation
The encapsulation efficiency of miR-181a was quantified indirectly by fluorescence displacement assay using SYBR® Gold (Thermo Scientific, Montréal, QC, Canada). LNP were prepared at a final miR181a concentration of 100 nM in dextrose 5% and were centrifuged at 14,000 rpm for 1 h. miRNA in the supernatant was quantified against a calibration curve of miR-181a (6.25-50 nM) using a Safire microplate reader (λex/em = 495/537) (Tecan, Seestrasse, Switzerland). All experiments were realized in triplicate. miRNA encapsulation efficiency (%) was calculated as follow:
Physicochemical characterization of LNP
Dynamic Light Scattering (DLS) was used to measure the hydrodynamic diameter of the resulting LNP with or without melphalan and/ or miRNA. All the measurements were done at 20°C using a Malvern Zetasizer Nano ZS (Malvern, Worcestershire, UK). Size measurements are reported using the Z-Average value. ζ-potential measurements were realized at 20°C using the Smoluchowski model. For both DLS and ζ-potential measurements, nanoparticles were diluted 10× in dextrose 5% (final volume 1 mL). The morphology of nanoparticles was observed by transmission electron microscopy (TEM) at University of Montreal, Canada where 10 μL of each dispersion of liposomes, either fixed with 1% glutaraldehyde or unfixed, was dropped on a carbon-formvarcoated nickel grid for 10 min. Grids containing fixed liposomes were washed with water prior to staining. 10 μL of 1.5% Uranyl acetate was dropped on the grid for 30 s. The excess of sample and negative stain solution was blotted with Whatman filter paper and grid was air-dried prior the observation in TEM. Examination was performed with a Philips CM100 TEM. Electron micrographs were captured using an AMT XR80 digital camera.
Cell culture
In this investigation, two types of human Rb cells were used: primary cells from a Rb patient, and Rb cell line Y-79 (ATCC; Manassas, VA, USA). The Y-79 cell line is commonly used in biomedical research as an in-vitro model system. Human Rb tumor samples were obtained from the primary-site intra-ocular Rb of a young patient at CHU SainteJustine (Montreal, QC, Canada). The human specimen is from the Ethic Committee of CHU Sainte-Justine and the experiment has been done accordingly. Primary human Rb cell culture was performed as we previously described [9] .
Uptake assays of LNP by Rb cells

Uptake of DiI-labeled LNP
To assess transfection capability, fluorescent LNP were prepared using indocarbocyanine dye (Vybrant CM-DiI Cell-Labeling Solution, V22888, Life Technologies, Canada), in a composition of CSL3/DSCP/ Cholesterol/DiI/DSPE-PEG 2000 50/10/36/1.5/2.5 mol%, as described in the LNP formulation section. Y-79 cells in culture were then treated with the resulting fluorescent nanoparticles and sequential microscopic images (Nikon Eclipse TE300, camera Nikon DS-Ri1) were taken by a 40× objective at t = 0, 2, 4, and 24 h after transfection.
Internalization pathway
To investigate internalization (transfection) pathways, Y79 cells ( Geomean fluorescent intensity was calculated using FlowJo software. Experiments were realized in triplicates. 
Uptake inhibition by fluorescence microscopy
Viability assays (in-vitro)
To analyze the viability of Rb cells in-vitro, metabolically active cells were stained with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Prestoblue; ThermoFisher Scientific, Canada) and fluorometric changes were quantified using a spectrofluorometer (Clariostar; BMG Labtech, Germany). Briefly, Prestoblue solution is a blue-colored compound that turns pink upon oxidation in the presence of live cells. The amount of absorbance reflects the number of viable cells. Here, Prestoblue was dispersed into each well containing the same number of cultured cells (10 μL Prestoblue in 100 μL cultured cell media in a 96 well plate), and the cultures were incubated for 24 h at 37°C. Then the fluorescence signal from the wells were measured and the values were normalized to baseline readings obtained at time zero.
Computational prediction of miRNA targets
To identify some of the miR-181a targets, the open source TargetScan 7.1 algorithm [27, 28] was employed. This program combines thermodynamics-based modeling of RNA:RNA duplex interactions with comparative sequence analysis to predict the miRNA targets conserved across multiple genomes. While several genes were close matches, in this study we focused on apoptosis regulators such as BAX, B-cell lymphoma 2 (Bcl-2), and mitogen-activated protein kinase 1 (MAPK1) (see Table 1 ).
Total RNA extraction and quantitative RT-PCR
In a 6 well plate, 0.8 × 10
6 Y-79 cells/well were incubated with LNP/miR (miR-181a vs. scrambled miRNA) for 36 h. Then, the total RNA was extracted and purified using the RNeasy kit (Qiagen) according to the manufacturer's instructions and quantified using the NanoDrop (ThermoFisher Scientific, Canada). The RNA extracted from cells treated with miR-181a was used to synthesize cDNA as previously reported [13] . First-strand cDNA synthesis and quantitative PCR analysis of samples were performed on a 7900HT real-time PCR system (Applied Biosystems, Mulgrave, VIC, Australia) with iTaq SYBR Green Supermix with ROX (Bio-Rad) as previously described [29] . Primers for BAX, Bcl-2, MAPK1 and human β-actin were purchased (AlphaDNA, Canada); β-actin (housekeeping gene) was used as an internal controlsee Table 1 . The PCR amplification protocol involved 40 cycles of denaturation at 94°C for 30 s, primer annealing at 55°C for 10 s, and primer extension at 72°C for 1 min. Each sample was then analyzed in triplicate. The mRNA level of each gene was quantified relative to β-actin and the fold change of gene expression in control and treated samples was determined according to the following equation: fold change = 2 -∆∆Ct [13] .
In-vitro treatment with melphalan
Y-79 cells were cultured in a 96 well plate (50 k cells/well) and treated with 10 μM, 20 μM, and 40 μM melphalan for 24 h. The cell viability was then assessed. In addition, the effect of LNP containing 12.5 μM melphalan (LNP/melphalan) on the same number of cultured cells incubated for 24 h was assessed. Finally, cells were treated with lipid complexes (LNP vs. LNP/miR-181a vs. LNP/miR-181a + LNP/ melphalan vs. LNP/miR-181a/melphalan) for 48 h. All wells contained the same concentration of lipids (117 μM), and wells in the LNP/miR181a + LNP/melphalan group and LNP/miR-181a/melphalan group contained 25 nM miR-181a and 4 μM melphalan. Cell viability results are presented in Section 3.
Animal experiments
All experiments were performed according to protocols approved by the CHU Sainte-Justine Animal Care Committee. Nine male SpragueDawley rats (325-350 g) were purchased from Charles River Laboratories International, Inc. (St-Constant, Quebec, Canada) and used to develop the xenograft Rb model. Each animal then received a daily subcutaneous injection of 10 mg/kg Cyclosporine-A (Sandimmune, Novartis, Canada) to suppress the immune system. This procedure was continued throughout the entire experiment. Following each injection, the overall condition of each animal was closely monitored. As seen in Fig. 1 , on day 15 every animal received Y-79 cells in the vitreous of both eyes as previously described [30] see Fig. S1 in Supplementary information). Briefly, a Hamilton syringe equipped with a sharp 30-gauge needle was used to inject a total volume of 5 μL containing 500 k cells suspended in human plasma (Millipore Sigma, Oakville, Canada) in the vitreous of each eye without damaging the posterior segment or the lens in the eye. The cells were then left to grow and develop a cloud of cells for 6 days. A RetCam (Natus Medical, Pleasanton, CA) was used Table 1 The sequence of primers used in identifying the effect of miR-181a on several target genes by PCR analysis.
Forward 5′-3′
Reverse 5′-3′ β-Actin CTGCGGCATTCACGAAACTAC ATCTCTTTCTGCATCCTGTCCG Bcl-2  GGTGAACTGGGGGAGGATTG  GTGCCGGTTCAGGTACTCAG  BAX  TGGCAGCTGACATGTTTTCTGAC  TCACCCAACCACCCTGGTCTT  MAPK1  TTCCAAGGGCTACACCAAGTC  GGAGTCAGCATTTGGGAACAG to locate and assess the development of the tumor in the vitreous. One eye of each animal was then treated with 5 μL of the LNP, and the contralateral eye (control) received 5 μL of saline. The animals were randomly divided into 3 groups; i) melphalan (n = 3), ii) LNP/miR-181a (n = 3), iii) LNP/miR-181a/melphalan (n = 3). The animals were sacrificed 48 h after having received the treatment. The concentration of melphalan and miR-181a in the LNP were measured to be 85 nM and 50 nM, respectively. The weight and general appearance of the animals were also recorded every other day throughout the experiments.
Quantification of the in-vivo treatment
The enucleated eyes were washed with PBS 1×. Under the microscope, each eye was then quickly dissected and drained inside a 6-well plate. The vitreous is viscous, therefore, to collect the maximum number of Rb cells in the well, the dissected tissue was again thoroughly washed with PBS 1×. The recovered cells were re-suspended by repeated pipetting to break up agglomerated cells. A classic hemocytometer was used to count the number of live and dead cells in each sample. This procedure was repeated 3 times for each eye and averaged. Then, the ratio of treated live cells and untreated live cells was calculated (see Eq. (3)) and plotted for each animal using a GraphPad Prism software for further analysis. In a pilot study, the recovered cells from the eye of a single rat were stained with syntaxin (cytofix/cytoperm BD kit cat#555028) as well 
Statistical analysis
Unless stated otherwise, all of the experiments were performed in triplicate, and the experimental data were expressed as mean ± standard deviation (SD). Unless stated otherwise, all of the data were analyzed by t-test analysis using Prism software. In all cases, significance was assumed at p < .05.
Results
Preparation of LNP loaded with miR-181a and melphalan
LNP were composed of: (i) a switchable cationic lipid reported to change conformation at acidic pH and trigger endosomal escape, (ii) DSPC to provide bilayer structure, (iii) cholesterol to improve membrane fluidity, and (iv) DSPE-PEG 2000 to ensure colloidal stability. LNP used to encapsulate melphalan, miR-181a or both were prepared by hydration of the lipid film. They exhibited a spherical shape as seen by TEM ( Fig. 2A and B) and had a hydrodynamic diameter of 173 nm with a monodisperse distribution ( Table 2) . Melphalan was incorporated into the lipid phase with a 93% encapsulation efficiency. Melpahlan stability in LNP at 37°C and 25°C was also analyzed by HPLC-UV (see Fig. S2 in Supplementary information).
Encapsulation of miR-181a or melphalan did not affect the hydrodynamic diameter nor the polydispersity of the LNP (Table 2) . Encapsulation could be confirmed by potential zeta (ζ) changes. LNP Fig. 1 . Overview of the in-vivo experimental plan. At day 21 prior to treatment and again at day 24 prior to sacrifice, the tumor was imaged by a RetCam apparatus. exhibited cationic surface charge due to the cationic switchable lipid, with or without melphalan. Incubation with miR-181a partially reduced the surface charge, resulting in a decrease in zeta potential. The particles remained cationic since the cationic lipid was in excess compared to the anionic nucleic acid (charge ratio N/P = 4).
High transfection efficiency of LNP
To assess capability of LNP to transfect Y-79 cells, fluorescently labeled LNP were used ( Table 2 , Fig. 3A and B) . Sequential images (also see Fig. S3 in Supplementary information for t = 0 and t = 24 h) show that fluorescent LNP had a strong interaction with Y-79 cells within the first few hours of incubation. Endocytosis studies (flow cytometry and fluorescent microscopy analysis) suggested that clathrin, caveolae, and micropinocytosis pathways were involved in the endocytotic mechanism of LNP (see Fig. S4 and S5 in Supplementary information). These results indicate that all cells were in fact transfected by the LNP.
Viability of Rb cells after miR-181a treatment
The potential toxicity of LNP formulation on a dose-dependent manner was assessed. Importantly, LNP was well tolerated by Y-79 and resulted in slightly higher viability readings (Fig. 4A) . miR-181a loaded into LNP was then incubated with two types of Rb cells: primary human Rb cells freshly collected from a patient and immortalized human Y-79 cells. Treatment with 25 nM miR-181a significantly reduced viability of primary Rb cells at 24 h and 48 h (Fig. 4B and C) . In comparison, miR181a only exerted its effect on Y-79 cells after 48 h (Fig. 4D ). Shorter and longer incubation times (24 h and 72 h) did not significantly improve the therapeutic efficacy on Y-79 cells (see Fig. S6 in Supplementary information).
Target gene analysis
Target gene analysis of MAPK1, Bcl-2, and BAX in Y-79 cells showed that treatment with miR-181a significantly decreased the expression of MAPK1 and Bcl-2, whereas it significantly increased the expression of BAX (Fig. 5) . The anti-proliferative effect was also confirmed by the lower concentration of RNA extracted from cells treated with LNP/miR181a versus control (see Fig. S7 in Supplementary information).
Liposomal treatment of melphalan and miR-181a
The cytotoxic effect of melphalan was confirmed by treating Y-79 with increasing concentrations of melphalan (Fig. 6A) . 20 μM was selected as the effective concentration of melphalan to reduce Y-79 cell viability by near 50% (EC50). Interestingly, encapsulation of melphalan improved its cytotoxic effect, since treatment with 12.5 μM encapsulated melphalan resulted in a total inhibition of cell viability (Fig. 6B) . Note that the viability of cells treated with LNP/miR-181a in Fig. 6B was compared to the viability of cells treated with the same amount of LNP only, to consider the impact of LNP on cell viability (see Fig. 4A ).
Compared to the LNP, cells treated with LNP/miR-181a reduced cell viability by 27%. When cells treated with LNP/miR-181a were co-delivered with LNP/melphalan, viability was reduced by 33%. Finally, when both actives (miR-181a and melphalan) were delivered within the same LNP (LNP/miR-181a/melphalan), an additional 10% decrease in cell viability (44%) was observed (Fig. 6C) .
In-vivo Rb treatment
The Rb tumor model was developed according to [30] . Y-79 cells were injected in the vitreous of rats and tumor growth was monitored by RetCam before (day 21) and after (day 24) the treatment (see Fig. 1 ). While the images are two dimensional and not quantitative (see Fig. S8 in Supplementary Information), there is a clear difference between the morphology of the tumors in the images acquired from the untreated and the treated eyes. At the end of the treatment, eyes were enucleated and residual tumor cells were extracted from the vitreous. In a separate Calculation is detailed in Section 2. %EE: encapsulation efficiency; N/D: not determined; N/A: not applicable.
Fig. 3. Fluorescence microscopy. A) Images of Y-79 cells incubated with fluorescent LNP for 2 h and B) 4 h at 37°C (exposure time 300 ms, objective 40×).
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experiment, the cancerous nature of the recovered Rb cells was established (protocol explained in S9 of the Supplementary Information).
The ratio between live cells in treated eye vs. untreated eye for each rat was calculated and plotted in Fig. 7 . LNP/miR-181a treatment reduced the number of tumor cells by 37% as compared to free melphalan, a routine clinical treatment, whereas co-delivery of melphalan and miR181a reduced the number of viable cells by 72%, which demonstrated the potency of this combined treatment. This improvement could be due to the miR-181a administration as well as the melphalan encapsulation into LNP, as suggested by in-vitro experiments shown in Fig. 6B .
Discussion
Drug delivery to the sensitive ocular organ has long been the focus of many in the scientific community [31, 32] . In the case of Rb, common clinical approaches are the intra-arterial, intra-venous, preocular, intravitreal administration, or direct intra-ophthalmic artery catheterization for administration of chemotherapeutic agents such as melphalan [33, 34] . One of the main challenges in ophthalmic drug delivery via systemic administration however, is the presence of the blood-retinal barrier [35] . While there has been advances in drug delivery across this barrier [36, 37] , current conventional clinical techniques do now allow a sufficient concentration of melphalan to readily permeate through the barrier to treat sub-retinal Rb [38] . Treatment becomes even more challenging when the tumor starts to seed into the vitreous. In that case, melphalan may be injected intra-vitreally in multiple sessions [6, 7] . Evidently, systemic administration of chemotherapeutic elements, especially for multiple sessions, can further increase the cytotoxic sideeffects. Fortunately, today's technology allows precise and accurate intra-vitreal injections [39] , but due to the relatively small vitreal space, drug release can face elimination [40] . Nanoparticles, especially liposomes, have been developed for treatment of ocular disorders due to their improved drug retention, ability to sustain drug release, and improved cellular uptake [41] [42] [43] . Indeed, in this investigation, employment of pH-sensitive cationic switchable liposomes loaded with therapeutic agents have shown an increase in drug uptake in the confined vitreal space for the treatment of seeded Rb cells.
In-vitro
Fluorescent LNP demonstrated a strong affinity to Y-79 (see Fig. 3A and B). This is consistent with our previous observations with other cell lines [26] . Also in agreement with our previous reports, LNP were well tolerated by the cells in the culture medium. Interestingly, despite reported toxicity of cationic lipids [44] , we observed that higher LNP concentration (not loaded) in the culture medium led to increase in cell viability (Fig. 4A . Perhaps this is not surprising; the LNP used in this investigation are consisted of cationic switchable lipids, as well as cholesterol and phospholipids, which can consider as nutrition for the abnormally thriving Y-79 cells [45] . When the readily endocytosed LNP are loaded with therapeutics (miR-181a and melphalan), the higher uptake translates to more toxic effects as seen in Fig. 6A . This favorable biocompatibility profile coupled with a high transfection ability is a main advantage of the switchable lipids used in this project. Their endosomal escape ability allows a high transfection efficiency without the need to increase dosage and without toxicity. According to Fig. 4B -D, the viability of cells transfected with LNP/ miR-181a are significantly lower than that of those transfected with LNP containing a randomly scrambled miRNA (negative control). These results are in agreement with the previously reported effect of miR181a on other cell lines [16, 17] . The decrease in cell viability in primary cells is manifested as early as 24 h after transfection (Fig. 4B ) while for the genetically immortalized Y-79 cells, it takes longer to become significant (Fig. 4D) . Indeed, primary cells are closer to clinical Rb model than the cell line. High therapeutic effect of LNP complex on primary cells therefore signifies a higher therapeutic potency in the clinical setting. Fig. 4B also suggests that 25 nM is the optimum concentration of miR-181a that is required to substantially reduce but not entirely flatten the viability of the primary cells. For Y-79 cells, treatment with miR-181a at 25 nM also showed a stronger therapeutic effect (Fig. 4D) . Extension of the incubation time with LNP/miR-181a does not significantly improve the therapeutic outcome for the primary (Fig. 4C ) nor for the Y-79 cells (see Fig. S6A and S6B in Supporting information). It is therefore evident that combining miR-181a with more established therapies such as chemotherapeutics could play an important complimentary role for the treatment of Rb.
Once inside the cytoplasm, miRNAs generally bind to the 3'-UTR (untranslated region) of their target gene on the messenger RNA (mRNA) and regulate protein production by destabilizing the mRNA and thereby silencing translation [46] . The gene regulatory role of miR181a and its complex cellular signaling pathways are poorly understood. While an in-depth investigation of the complex overlapping cellular pathways does not fall into the scope of this investigation, according to Fig. 5 , overexpression of miR-181a results in significant downregulation in the expression of MAPK1 (1.6 folds) that plays a critical role in regulating cell proliferation [47, 48] . The results presented in Fig. 5 also indicate that overexpression of miR-181a downregulates the expression of Bcl-2 (3.2 folds) that is significantly overexpressed in Rb tumors [49] . Finally, overexpressed miR-181a upregulates the expression of BAX (3.6 folds), the loss of which has been correlated with massive choroidal invasion and Pathological Tumor-Node-Metastasis [49] . These findings could imply that miR181a favors cellular signaling pathways that lead to an apoptotic state.
Apart from miR-181a, evidence shows that LNP also increases the efficiency of melphalan uptake. Encapsulation of melphalan in lipid carriers have been shown effective for drug delivery [50] . In our case, treatment with LNP/melphalan at 12.5 μM arrests cellular proliferation while free melphalan at 20 μM reduces cell viability by only a half ( Fig. 6A and B) . This improved efficacy of melphalan when encapsulated into LNP might be due to the favorable uptake of the LNP by the cells (Fig. 3) , as well as the fusion ability of the switchable liposomes [26] , resulting in improved melphalan delivery into the cytosol. The enhanced uptake capability of LNP, the therapeutic effects of miR181a, and the toxicity of melphalan indicates that indeed the two agents have a complementary therapeutic effect on Rb cells as seen in Fig. 6C . 
In-vivo
In order to assess the complementary therapeutic effect of melphalan and miR-181a in an in-vivo setting, bilateral Rb tumor was developed in a rat xenograft model. Each animal then received treatment (melphalan, LNP/miR-181a, or LNP/miR-181a/melphalan) in one eye while the contralateral eye served as a control. Understandably, tumor growth rate can vary significantly among the subjects, however, it is fair to assume that this rate is comparable between the eyes of the same animal. By comparing the number of live cells obtained from the treated eye versus the number of live cells obtained from the untreated one, the efficiency of the treatments was assessed. This comparison is defined as the coefficient C in Eq. (3) which quantifies how tumor cells were affected by each treatment (note that a lower C value signifies a higher rate of cell death). According to Fig. 7 , the coefficient C is higher for rats treated with melphalan or LNP/miR-181a than it is for rats treated with a combination of the two agents in a single carrier (LNP/ miR-181a/melphalan).
Administered at moderate doses but in multiple sessions, melphalan has proven to have the most potent chemotherapeutic effect to combat seeded Rb [51] . Nevertheless, clinical studies suggest that multiple injections of melphalan can result in a decreased electroretinogram response (i.e. damage vitreous cell types in the retina) [6] . On the other hand, miR-181a can regulate the expression of several influential genes (such as MAPK1, Bcl-2, and BAX) that are responsible for cell proliferation and apoptosis [47] [48] [49] . Despite its promising role in impairing Rb, evidence suggests that miR-181a cannot entirely eliminate Rb if unassisted. Therefore in this study, we proposed co-delivery of the two agents to benefit from their complementary therapeutic effects. Indeed, co-delivery is an attractive avenue that can inspire the benefit of multiple therapeutic agents at once [24, 52] . However, it can also increase inherent complications of individual interventions (e.g. potential incompatibility and tissue toxicity) [53] . In order to minimize the risks, the therapeutic complexes can be engineered to deliver their load directly to their target cells. Numerous studies have shown that LNP can significantly improve efficiency in ocular drug delivery [21, [54] [55] [56] . In addition to reports of successful incorporation of melphalan in lipid-based formulations [57] [58] [59] , the LNP used in this investigation are highly stable in the serum [26] , and their cationic nature makes them perfect candidates to couple with the negatively charged nucleotides of the miR-181a. Consequently, we designed and developed a lipid-based complex to co-deliver two therapeutic agents specifically to the cytoplasm of target Rb cells and increase efficiency and therapeutic impact.
Conclusion
In search of an alternative treatment for Rb, we proposed pH-sensitive cationic LNP to co-deliver miR-181a and melphalan. We have demonstrated that encapsulation of melphalan in liposomes drastically improved its efficiency, which was further complimented by the addition of miR-181a. Today, intra-vitreal injection has become one of the most commonly performed procedures in ophthalmology; therefore, it is reasonable to invest in a technology that can enhance drug delivery and efficiency in the eye. However, as with any novel formulation, it is imperative to examine its biocompatibility with the ocular tissues. The great promise of co-delivery of miR-181a and melphalan, via the recently developed switchable LNP, is summarized in its potential to improve the tolerated dose of the medication. This allows for safe increase of the administered dose thereby an increase in the efficiency of the treatment without any increase in the toxic side effects.
